Antibodies in Myeloma: Practical Applications for Nurses

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Ropeginterferon alfa-2b showed superior efficacy over anagrelide in the SURPASS-ET trial for essential thrombocythemia, with higher durable response rates and greater JAK2 allele burden reduction.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Treatment with venetoclax plus hypomethylating agents yielded improved response rates among adult patients with myelodysplastic syndrome.